Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01885195 · ClinicalTrials.gov registry record · Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors
A Phase 2 study of Solid Tumor and Hematologic Malignancies, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT01885195 is a Phase 2 study of Solid Tumor and Hematologic Malignancies that has completed, run by Pfizer. The registered enrollment target is 110 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT01885195, a Phase 2 study of Solid Tumor and Hematologic Malignancies, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
Conditions Studied
Interventions
- DRUG MEK162
Study Locations (20)
Florida
- Florida Cancer Specialists Florida Cancer Specialists (31 - Fort Myers
- Memorial Cancer Institute Memorial Healthcare System - Hollywood
- Cancer Specialists of North Florida - Jacksonville
- Mt. Sinai Comprehensive Cancer Center - Miami Beach
- Ocala Oncology Center Dept. of Ocala Oncology Center - Ocala
- Cancer Centers of Florida PA Cancer Centers of FL-Orlando-4 - Ocoee
Connecticut
- Yale University School of Medicine Yale Cancer Center - New Haven
- Whittingham Cancer Center Norwalk Hospital - Norwalk
- Eastern Connecticut Hematology & Oncology Associates Dept. of ECHO - Norwich
- Hematology Oncology PC Stamford Hospital - Stamford
Arizona
- Arizona Oncology Associates AZ Oncology Assoc. - Phoenix
- Arizona Oncology Associates HOPE Division - Phoenix
- Arizona Oncology Associates PC- NAHOA - Sedona
California
- PCR Oncology - Pismo Beach
- University of California Davis Cancer Center UC Davis Cancer (3) - Sacramento
Alabama
- University of South Alabama / Mitchell Cancer Institute Univ South Alabama - Mobile
Alaska
- Alaska Oncology and Hematology AOH (2) - Anchorage
Arkansas
- Highlands Oncology Group Highlands Oncology Group (22) - Fayetteville
Colorado
- Rocky Mountain Cancer Centers USOR - Boulder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2017-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01885195
The ClinicalTrials.gov registry entry for NCT01885195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor and Hematologic Malignancies appearing as the primary indexed condition, and to 1 intervention - of which MEK162 is the first listed.
NCT01885195 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, Connecticut, Arizona.
Frequently Asked Questions
What is clinical trial NCT01885195 about?
NCT01885195 is a clinical study titled "MEK162 for Patients With RAS/RAF/MEK Activated Tumors". The purpose of this signal seeking study is to determine whether treatment with MEK162 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study
What is the current status of trial NCT01885195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2013-10-10. Estimated completion is 2017-04-11.
What conditions does trial NCT01885195 study?
This clinical trial studies the following conditions: Solid Tumor and Hematologic Malignancies.
What interventions are being tested in trial NCT01885195?
The interventions under investigation include: MEK162 (DRUG).
Who is sponsoring clinical trial NCT01885195?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01885195 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.